Brad S. Kahl
About
Brad S. Kahl is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology.
According to data from OpenAlex, Brad S. Kahl has authored 385 papers receiving a total of 11.3k indexed citations (citations by other indexed papers that have themselves been cited), including 325 papers in Pathology and Forensic Medicine, 181 papers in Genetics and 172 papers in Oncology. Recurrent topics in Brad S. Kahl's work include Lymphoma Diagnosis and Treatment (325 papers), Chronic Lymphocytic Leukemia Research (180 papers) and Viral-associated cancers and disorders (72 papers). Brad S. Kahl is often cited by papers focused on Lymphoma Diagnosis and Treatment (325 papers), Chronic Lymphocytic Leukemia Research (180 papers) and Viral-associated cancers and disorders (72 papers). Brad S. Kahl collaborates with scholars based in United States, Canada and United Kingdom. Brad S. Kahl's co-authors include Ian W. Flinn, Jennifer R. Brown, John P. Leonard, Richard I. Fisher, Randy D. Gascoyne, Ranjana H. Advani, Fangxin Hong, Nancy L. Bartlett, Bruce D. Cheson and David T. Yang and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Brad S. Kahl
370 papers receiving 11.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Brad S. Kahl United States | 49 | 7.8k | 5.6k | 5.1k | 2.4k | 1.8k | 385 | 11.3k | ||
| Franck Morschhauser France | 56 | 8.8k 1.1× | 6.7k 1.2× | 3.7k 0.7× | 1.9k 0.8× | 2.3k 1.3× | 447 | 12.3k | ||
| Francesc Bosch Spain | 48 | 5.6k 0.7× | 3.4k 0.6× | 4.3k 0.8× | 2.0k 0.8× | 2.1k 1.1× | 243 | 8.7k | ||
| Myron S. Czuczman United States | 50 | 6.5k 0.8× | 4.6k 0.8× | 3.5k 0.7× | 2.0k 0.8× | 1.9k 1.1× | 241 | 10.4k | ||
| Laurie H. Sehn Canada | 55 | 10.6k 1.4× | 7.3k 1.3× | 4.2k 0.8× | 1.6k 0.7× | 1.9k 1.1× | 353 | 13.4k | ||
| Bruce D. Cheson United States | 37 | 5.3k 0.7× | 3.7k 0.7× | 3.0k 0.6× | 1.9k 0.8× | 1.4k 0.8× | 130 | 9.6k | ||
| Morton Coleman United States | 47 | 4.8k 0.6× | 3.0k 0.5× | 3.3k 0.6× | 1.6k 0.7× | 1.2k 0.7× | 306 | 8.2k | ||
| Kerry J. Savage Canada | 51 | 10.6k 1.4× | 7.4k 1.3× | 3.0k 0.6× | 1.5k 0.6× | 2.8k 1.6× | 305 | 13.4k | ||
| Vincent Ribrag France | 46 | 3.6k 0.5× | 4.6k 0.8× | 1.7k 0.3× | 2.0k 0.8× | 1.5k 0.9× | 309 | 7.9k | ||
| Kristie A. Blum United States | 41 | 4.4k 0.6× | 2.6k 0.5× | 3.9k 0.8× | 1.4k 0.6× | 1.4k 0.8× | 207 | 6.7k | ||
| Emili Montserrat Spain | 66 | 9.4k 1.2× | 4.1k 0.7× | 10.5k 2.0× | 3.4k 1.4× | 5.3k 2.9× | 296 | 16.3k |
Countries citing papers authored by Brad S. Kahl
Since
Specialization
Citations
This map shows the geographic impact of Brad S. Kahl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brad S. Kahl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brad S. Kahl more than expected).
Fields of papers citing papers by Brad S. Kahl
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Brad S. Kahl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brad S. Kahl. The network helps show where Brad S. Kahl may publish in the future.
Co-authorship network of co-authors of Brad S. Kahl
This figure shows the co-authorship network connecting the top 25 collaborators of Brad S. Kahl. A scholar is included among the top collaborators of Brad S. Kahl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brad S. Kahl. Brad S. Kahl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Wang, Yucai, Melissa C. Larson, Anita Kumar, et al.. (2024). Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma.. Journal of Clinical Oncology. 42(16_suppl). 7006–7006.
2.
Ghobadi, Armin, Michael P. Rettig, Amanda F. Cashen, et al.. (2023). Blinatumomab consolidation post–autologous stem cell transplantation in patients with diffuse large B-cell lymphoma. Blood Advances. 8(3). 513–522.
3.
Hess, Brian, Nasheed Hossain, Volkan Beylergil, et al.. (2023). SWOG 2114: A RANDOMIZED PHASE II TRIAL OF CONSOLIDATION THERAPY FOLLOWING CD19 CAR T‐CELL TREATMENT FOR RELAPSED/REFRACTORY LARGE B‐CELL OR GRADE IIIB FOLLICULAR LYMPHOMA. Hematological Oncology. 41(S2). 839–840.
4.
Evens, Andrew M., Fangxin Hong, Thomas M. Habermann, et al.. (2020). A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408. Clinical Cancer Research. 26(17). 4468–4477.
5.
Hamadani, Mehdi, John Radford, Carmelo Carlo‐Stella, et al.. (2020). Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 137(19). 2634–2645.
6.
Stephens, Deborah M., Hongli Li, Heiko Schöder, et al.. (2019). Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood. 134(15). 1238–1246.
7.
Rule, Simon, Martin Dreyling, André Goy, et al.. (2019). Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 Years of Extended Follow-up. Blood. 134(Supplement_1). 1538–1538.
8.
Scott, David W., Rebecca L. King, Annette M. Staiger, et al.. (2018). High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood. 131(18). 2060–2064.
9.
Flinn, Ian W., Susan O’Brien, Brad S. Kahl, et al.. (2017). Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies. Blood. 131(8). 877–887.
10.
Ford, Robert, Michael O’Neal, Brad S. Kahl, et al.. (2016). Investigator and independent review committee exploratory assessment and verification of tumor response in a non-Hodgkin lymphoma study. Leukemia & lymphoma. 58(6). 1332–1340.
11.
Rule, Simon, Martin Dreyling, Gregory P. Hess, et al.. (2016). Overall survival outcomes in patients with mantle-cell lymphoma (MCL) treated with Ibrutinib in a pooled analysis of 370 patients from 3 international open-label studies. Haematologica.
12.
Barr, Paul M., Hongli Li, Catherine Spier, et al.. (2015). Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. Journal of Clinical Oncology. 33(21). 2399–2404.
13.
Roberts, Andrew W., Matthew S. Davids, John M. Pagel, et al.. (2015). Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. New England Journal of Medicine. 374(4). 311–322.
14.
Kahl, Brad S., Fangxin Hong, Michael E. Williams, et al.. (2014). Rituximab Extended Schedule or Re-Treatment Trial for Low–Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402. Journal of Clinical Oncology. 32(28). 3096–3102.
15.
Flinn, Ian W., Richard van der Jagt, Brad S. Kahl, et al.. (2014). Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 123(19). 2944–2952.
16.
Smith, Mitchell R., Hailun Li, Leo I. Gordon, et al.. (2012). Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90–Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499. Journal of Clinical Oncology. 30(25). 3119–3126.
17.
Gordon, Leo I., Fangxin Hong, Richard I. Fisher, et al.. (2012). Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496). Journal of Clinical Oncology. 31(6). 684–691.
18.
Kenkre, Vaishalee P. & Brad S. Kahl. (2012). The Future of B-Cell Lymphoma Therapy: The B-Cell Receptor and its Downstream Pathways. Current Hematologic Malignancy Reports. 7(3). 216–220.
19.
Markovina, Stephanie, Natalie S. Callander, Shelby L. O’Connor, et al.. (2008). Bortezomib-Resistant Nuclear Factor-κB Activity in Multiple Myeloma Cells. Molecular Cancer Research. 6(8). 1356–1364.
20.
Kujawski, Lisa, Walter Longo, Eliot C. Williams, et al.. (2007). A 5-Drug Regimen Maximizing the Dose of Cyclophosphamide is Effective Therapy for Adult Burkitt or Burkitt-like Lymphomas. Cancer Investigation. 25(2). 87–93.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Franck Morschhauser Breakdown of academic impact, for papers by Francesc Bosch Breakdown of academic impact, for papers by Myron S. Czuczman Breakdown of academic impact, for papers by Laurie H. Sehn Breakdown of academic impact, for papers by Bruce D. Cheson Breakdown of academic impact, for papers by Morton Coleman Breakdown of academic impact, for papers by Kerry J. Savage Breakdown of academic impact, for papers by Vincent Ribrag Breakdown of academic impact, for papers by Kristie A. Blum Breakdown of academic impact, for papers by Emili Montserrat